Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Ho-Kyoung | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Lee, Heon-Jeong | - |
dc.contributor.author | Kwon, Do-Young | - |
dc.contributor.author | Kim, Leen | - |
dc.date.accessioned | 2021-09-07T09:59:17Z | - |
dc.date.available | 2021-09-07T09:59:17Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-08 | - |
dc.identifier.issn | 0924-2708 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111919 | - |
dc.description.abstract | Objective: Delirium is a life-threatening neuropsychiatric syndrome characterised by disturbances in consciousness, attention, cognition and perception. Antipsychotics are considered the drugs of choice in managing the symptoms of delirium. Paliperidone is a benzisoxazole derivative and the principal active metabolite of risperidone. In this study, we aimed to evaluate the efficacy of paliperidone for the treatment of delirium. Methods: A prospective open-label study of paliperidone for delirium treatment was performed with 6-day follow-up. Fifteen patients who met Diagnostic and Statistical Manual of Mental disorders, Fourth Edition criteria for delirium and had a score of 13 on the Delirium Rating Scale were recruited. The starting dose was 3 mg once a day and the dose was adjusted depending on the status of delirium. Daily assessments of the severity of delirium were evaluated using Memorial Delirium Assessment Scale (MDAS). Results: The mean daily maintenance dose of paliperidone was 3.75 +/- 1.06. The MDAS scores before and after treatment (day 7) were 23.60 +/- 6.31 and 11.33 +/- 5.45 (t = 6.78, p < 0.001), respectively. The intensity of delirium showed a statistically significant reduction in MDAS scores from the first day of treatment. No serious adverse effects were observed, and none of the patients discontinued paliperidone because of adverse effects. Conclusions: This study shows that low-dose paliperidone is effective in reducing behavioural disturbances and symptoms in delirium and is well tolerated in delirious patients. This trial is an open-label study with a small sample size, and further controlled studies will be necessary. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | CAMBRIDGE UNIV PRESS | - |
dc.subject | EXTENDED-RELEASE TABLETS | - |
dc.subject | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject | RATING-SCALE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | RISPERIDONE | - |
dc.subject | HALOPERIDOL | - |
dc.subject | DRUGS | - |
dc.title | Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Ho-Kyoung | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.contributor.affiliatedAuthor | Ko, Young-Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Heon-Jeong | - |
dc.contributor.affiliatedAuthor | Kwon, Do-Young | - |
dc.contributor.affiliatedAuthor | Kim, Leen | - |
dc.identifier.doi | 10.1111/j.1601-5215.2011.00568.x | - |
dc.identifier.scopusid | 2-s2.0-79960562350 | - |
dc.identifier.wosid | 000292829600007 | - |
dc.identifier.bibliographicCitation | ACTA NEUROPSYCHIATRICA, v.23, no.4, pp.179 - 183 | - |
dc.relation.isPartOf | ACTA NEUROPSYCHIATRICA | - |
dc.citation.title | ACTA NEUROPSYCHIATRICA | - |
dc.citation.volume | 23 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 179 | - |
dc.citation.endPage | 183 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | EXTENDED-RELEASE TABLETS | - |
dc.subject.keywordPlus | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | RATING-SCALE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | RISPERIDONE | - |
dc.subject.keywordPlus | HALOPERIDOL | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordAuthor | delirium | - |
dc.subject.keywordAuthor | DRS | - |
dc.subject.keywordAuthor | MDAS | - |
dc.subject.keywordAuthor | paliperidone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.